		डीपीसीओ 2013 के पैरा 4 वे	न तहत, अगस्त 2015 के आंकड़ों के आधारित, व	मूल्य की संगणना										
		Computation of Ceiling F	Price based on Aug-2015 Data under Para 4	of DPCO 2013										
						Number of Co	mpanies co	nsisting	of Market Share	of 1% & Above				4
	23.1	Atracurium	Injection 10 mg/ml	Per ML		Sum of MAT v	alue consid	ered fo	r price calculation	ı (in Lakhs)				212.12
						Sum of PTR pe	r unit consi	dered f	or price calculation	on				140.16
						Number of Pa	cks conside	red						4
						Average PTR								35.04
						Add : 16% Ret	ailer Margii	1						5.61
									(wef. 10.3.2016)					40.65
						% Reduction v			-					13.33%
						WPI Reduction								1.10
						Final Ceiling P	rice (withoι	t local t	axes) (wef. 01.4.	2016 or date of I	notification, whi	chever is late	er)	39.55
											Minimum Price	. ,		23.60
					S.O. 619(E) dated 26.02.2015						Maximum Price	- ( - /		40.43
					Ceiling Price as per NLEM 2011	49.99	Per ML				Average of all of	onsidered (F	Rs.)	35.04
					Deirved Ceiling PTR	43.09					Ceiling Price (R	s.)		40.65
			. =						TOTAL MAT	21,212,212				
S.	Unique	Composition as per	पैक विवरण	छाप	कंपनी	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	SKU wise	Qualify	Price per	Price per Unit
No.		NLEM	Pack Description	BRAND	Company						MAT %	(Y/N)	Unit (Rs.)	(Rs.) Considered
	NLEM											Y=Yes		
												N=No		
1		ATRACURIUM   M3A2	ACRIS 10 MG INJECTION 2.5 ML	ACRIS	GLAND PHARMA LIMITED	10 MG	2.5	ML	95.62	6,883,914	32.45%	Y	38.25	38.25
2		ATRACURIUM   M3A2	ARTACIL 10 MG INJECTION 5 ML	ARTACIL	NEON LABORATORIES LTD	10 MG	5	ML	117.99	1,324,821	6.25%	Y	23.60	23.60
3		ATRACURIUM   M3A2	ATCURON 10 MG INJECTION 2.5 ML	ATCURON	SUN PHARMA LABORATORIES LTD.	10 MG	2.5	ML	101.08	8,533,533	40.23%	Y	40.43	40.43
4	l l	ATRACURIUM   M3A2	TROYCURIUM 10 MG INJECTION 2.5 ML	TROYCURIUM	TROIKAA PHARMACEUTICALS LTD	10 MG	2.5	ML	94.71	4,469,944	21.07%	Υ	37.88	37.88

		Compu	tation of Ceiling Price based on Aug 2015	Data under Para 6 of D	PCO 2013							
						Number of C	Companies o	consisting of M	arket Share of	1% & Above		1
	6.4.3.1.2	ABACAVIR (A)+ LAMIVUDINE (B)	Tablet 60 mg (A) +30 mg (B)	Per Tablet		Sum of MAT	value consi	idered for price	e calculation (ir	n Lakhs)		7.97
						PTR under Co	onsideratio	n				16.51
						% Reduction	with comp	ared to Highes	t Price (averag	(e)		0.00%
						Reduction as	per Mono	poly condition				0.00
						PTR after Re	duction					16.51
						Add: 16% Re	etailer Marg	gin				2.64
						Ceiling Price	(without lo	cal taxes) (wef	. 10.3.2016)			19.15
						WPI Reducti	on wef 1.4.	2016 @ -2.710	5%			0.52
						Final Ceiling	Price (with	out local taxes	(wef. 01.4.20	16 or date of notificat	tion, whichever is later)	18.63
	of Item Under	consideration							TOTAL MAT	797,328		
	Unique No.	Composition as per NLEM	पैक विवरण	छाप	कंपनी	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit
	as per NLEM		Pack Description	BRAND	Company							Considered (Rs.)
1	6.4.3.1.2	ABACAVIR + LAMIVUDINE   J5B27	ALBAVIR PED 60/30 MG TABLET 60	ALBAVIR	MYLAN	60/30 MG	60	Tablet	990.47	797,328	100.009	6 16.51
B. Com	putation of Av	erage rate of Reduction under Monop	oly									
		S. No.	Drug(s)	Strength	Description	Route of Administrati on/ Dosage Form & packsize/pa cking, if any		S.O. number				Reduction with reference to the highest PTR under NLEM 2015 (%)
		:	1 Abacavir (A) + Lamivudine (B)	Tablet 600 mg (A)+	Abacavir (A) + Lamivudine (B)Tablet	Tablet		1817 (E) date	ed 18.5.2016			0.00
			+	300 mg (B)	600 mg (A)+ 300 mg (B)	+	1	Augus as De d		1		0.00
			1				1	Average Red	uction			0.00

	1				1							
		Computation	of Ceiling Price based on Aug 2015 Data under P	Para 6 of DPCO 2013	!							
		·				Number of C	ompanies (	consisting of N	larket Share o	of 1% & Above		
	6.4.3.1.3	Lamivudine (A) + Nevirapine (B) + Stavudine (C)	Dispersible Tablet 30 mg (A) + 50 mg (B) + 6 mg (C)	Per Tablet		Sum of MAT	value cons	idered for pric	e calculation	(in Lakhs)		2.40
						PTR under Co	onsideratio	n				5.23
						% Reduction	with comp	ared to Highes	st Price (avera	ge)		22.10%
								poly condition				1.16
						PTR after Re						4.07
						Add : 16% Re						0.65
								cal taxes) (we				4.72
								2016 @ -2.710				0.13
						Final Ceiling	Price (with	out local taxes	) (wef. 01.4.2	016 or date of notifi	cation, whichever is later)	4.59
	- Character								TOTAL MA	220 700		
	of Item Under	Composition as per NLEM	पैक विवरण	छाप	कंपनी	Strength	Pack Size		PTR (Rs.)	239,789 MAT (Rs.)	MAT (%)	Price per Uni
	as per NLEM	Composition as per NLEW	Pack Description	BRAND	कपना Company	Strength	Pack Size	Onit	PIR (RS.)	MAT (RS.)	IVIAT (%)	Considered (Rs.)
1	6.4.3.1.3	LAMIVUDINE + STAVUDINE + NEVIRAPINE   J5B30	TRIOMUNE BABY 30/6/50 MG TABLET DT 60	TRIOMUNE	CIPLA LTD.	30/6/50 MG	60	TABLET DT	313.86	239,789	100.00%	5.23
. Con		rerage rate of Reduction under Monopoly							1			
		S. No.	Drug(s)	Strength	Description	Route of Administrat ion/ Dosage Form & packsize/pa cking, if any		S.O. number	& date			Reduction with reference to the highest PTR under NLEM 2015 (%
			1 Lamivudine (A) + Nevirapine (B) + Stavudine (C)	150 mg (A) + 200 mg (B) + 30 mg (C)	Lamivudine (A) + Nevirapine (B) + Stavudine (C) 150 mg (A) + 200 mg (B) + 30 mg (C)	Tablet		4127(E) date	d 22.12.2016			22.1
								Average Red	uction			22.

						1						
		Computa	ation of Ceiling Price based on Aug 2	015 Data under Par	a 6 of DPCO 2013							
						Number of Co	ompan	ies coi	nsisting of Mark	et Share of 1%	& Above	1
	6.2.4.11	Pyrazinamide	Oral liquid 250 mg/5 ml	Per ML		Sum of MAT	value c	conside	ered for price ca	Iculation (in L	akhs)	1.55
		•				PTR under Co	onsider	ation			,	0.53
						% Reduction	with co	ompar	ed to Highest Pr	ice (average)		8.30%
						Reduction as	per M	onopo	ly condition			0.04
						PTR after Red	duction	1				0.49
						Add : 16% Re	tailer N	Margin	١			0.08
						Ceiling Price	(withou	ut loca	l taxes) (wef. 10	.3.2016)		0.57
						WPI Reduction	on wef	1.4.20	16 @ -2.7105%			0.02
						Final Ceiling I	Price (v	vithou	t local taxes) (w	ef. 01.4.2016	or date of notification, whichever is later)	0.55
A. L		Inder consideration							TOTAL MAT	154,850		
S.	Unique	Composition as per NLEM	पैक विवरण	छाप	कंपनी	Strength	Pack	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit
No.	No. as		Pack Description	BRAND	Company		Size					Considered
	per NLEM											(Rs.)
1	6.2.4.11	PYRAZINAMIDE   J4A10	PZA CIBA 250 MG SYRUP 100 ML	PZA CIBA	NOVARTIS INDIA LTD	250 MG	100	ML	53.14	154,850	100.00%	0.53
B. C	omputation	of Average rate of Reduct	ion under Monopoly									
		S. No.	Drug(s)	Strength	Description	Route of		S.O. ı	number & date			Reduction
						Administrati						with reference
						on/ Dosage						to the highest
						Form &						PTR under
						packsize/pa						NLEM 2015 (%)
						cking, if any						
		1	Pyrazinamide	Tablet 500 mg	PyrazinamideTablet 500 mg	Tablet		2195	(E) dated 23.6.2	016		4.30
		2	Pyrazinamide	Tablet 750 mg	PyrazinamideTablet 750 mg	Tablet		2195	(E) dated 23.6.2	016		20.75
		3	Pyrazinamide	Tablet 1000 mg	PyrazinamideTablet 1000 mg	Tablet		2195	(E) dated 23.6.2	016		3.38
			Pyrazinamide	Tablet 1500 mg	PyrazinamideTablet 1500 mg	Tablet		2569	(E) dated 27.7.2	016		4.75
								Avera	age Reduction			8.30

		Computa	ation of Ceiling Price based on A	Aug 2015 Data under	Para 6 of DPCO 2013							
						Number of Co	ompanies c	onsisting of M	arket Share of 19	% & Above		
	6.2.2.2	Ciprofloxacin	Oral liquid 250 mg/5ml	Per ML		Sum of MAT	alue consi	dered for price	e calculation (in L	.akhs)		0.06
			-			PTR under Co	nsideration	n .				0.64
						% Reduction	with compa	ared to Highes	t Price (average)			18.59%
						Reduction as	per Monop	ooly condition				0.12
						PTR after Red	luction					0.52
						Add: 16% Re	tailer Marg	in				0.08
						Ceiling Price (	without lo	cal taxes) (wef	. 10.3.2016)			0.60
						WPI Reduction	n wef 1.4.2	2016 @ -2.710	5%			0.02
						Final Ceiling F	rice (witho	out local taxes	(wef. 01.4.2016	or date of notification	on, whichever is later)	0.58
A. List	of Item Under	consideration							TOTAL MAT	5,978		
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Uni Considered
												(Rs.)
1	6.2.2.2	CIPROFLOXACIN   J1G1	REBAC 250 MG SYRUP 50 ML	REBAC	HYGEIA PHARMACEUTICALS	250 MG	50	ML	32.14	5,978	100.00%	0.64
B. Con	 nputation of Av	erage rate of Reduction un	der Monopoly									
		S. No.	Drug(s)	Strength	Description	Route of Administrati on/ Dosage Form & packsize/pa cking, if any		S.O. number	& date			Reduction with reference to the highest PTR under NLEM 2015 (%
		1	Ciprofloxacin	Tablet 250 mg	CiprofloxacinTablet 250 mg CiprofloxacinTablet 500 mg	Tablet Tablet		1686 (E) date				26.8 15.6
			Ciprofloxacin	Tablet 500 mg	Ciprofloxacin1ablet 500 mg  Ciprofloxacin200mg/100ml Injection	Injection		1686 (E) dated				13.2
		3	Ciprofloxacin	200mg/100ml Injection	Ciprolloxacin200mg/100ml injection	injection		, ,				
								Average Red	uction			18.59

		Computation	on of Ceiling Price based on Aug 2015 Data	under Para 6 o	f DPCO 2013							
						Number of Co	ompanies co	nsisting o	of Market Share	of 1% & Above	2	1
	6.4.3.4.3	Lopinavir (A) + Ritonavir (B)	Tablet 100 mg (A) + 25 mg (B)	Per Tablet		Sum of MAT	value consid	ered for p	orice calculation	(in Lakhs)		3.38
						PTR under Co	nsideration					19.66
						% Reduction	with compar	ed to Hig	hest Price (aver	age)		1.65%
						Reduction as	per Monopo	oly condit	ion			0.32
						PTR after Rec	duction					19.34
						Add : 16% Re						3.09
									wef. 10.3.2016)			22.43
						WPI Reduction						0.61
						Final Ceiling F	Price (withou	it local ta	xes) (wef. 01.4.2	016 or date of	f notification, whichever is later)	21.82
A. Li	st of Item l	Jnder consideration							TOTAL MAT	338,496		
-		P	पैक विवरण	छाप	कंपनी	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per
No.	No. as		Pack Description	BRAND	Company							Unit
	per											Considered
	NLEM											(Rs.)
1	6.4.3.4.3	RITONAVIR + LOPINAVIR   J5B35	EMLETRA JUNIOR 25/100 MG TABLET 60	EMLETRA	EMCURE PHARMACEUTICALS LTD	25/100 MG	60	TABLET	1179.43	338,496	100.00%	19.66
B. Co		of Average rate of Reduction under		ļ					<u> </u>	l		
		S. No.	Drug(s)	Strength	Description	Route of		S.O. nun	nber & date			Reduction
						Administrati						with
						on/ Dosage						reference to
						Form &						the highest
						packsize/pa						PTR under
						cking, if any						NLEM 2015
												(%)
1		1	Lopinavir (A) + Ritonavir (B)	Tablet 200		tablet		12	253(E) dated 29.	3.2016		1.65
1				mg (A) + 50								
				mg (B)					Dadt.	1		1.55
<u></u>				l .			l .	Average	Reduction			1.65

			-	1		1			1	1		1
		Comput	tation of Ceiling Price based on Aug 201	5 Data under Para 6 of	DPCO 2013							
		Comput	lation of coming thee based on Aug 201	Data unaci i aia o oi	1 10 2013	Number of C	omnanies co	onsisting of Market Shar	re of 1% & Abov	9		1
	9.1	Levodopa (A) + Carbidopa (B)	CR Tablet 200 mg (A) + 50 (B) mg	Per Tablet				lered for price calculation				2.72
	5.1	zerodopa (r.) - carbidopa (b)	en rablet 200 mg (ri) × 50 (b) mg	T CT TUBICE		PTR under Co			Jii (iii Lakiis)			3.62
								red to Highest Price (av	erage)			6.55%
						Reduction as						0.24
						PTR after Re						3.38
						Add : 16% Re	tailer Margi	n				0.54
								al taxes) (wef. 10.3.201	6)			3.92
								016 @ -2.7105%	ľ			0.11
						Final Ceiling	Price (withou	ut local taxes) (wef. 01.4	4.2016 or date of	of notification,	whichever is later)	3.81
						Ī	·					
A. Lis	t of Item	Under consideration							TOTAL MAT	272,197		
S.	Unique	Composition as per NLEM	पैक विवरण	छाप	कंपनी	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit
No.	No. as		Pack Description	BRAND	Company							Considered
	per											(Rs.)
	NLEM											
1	9.1	LEVODOPA + CARBIDOPA   N4A6	TIDOMET 200/50 MG TABLET CR 10	TIDOMET	TORRENT PHARMACEUTICALS LTD.	200/50 MG	10	TABLET CR	36.18	272,197	100.00%	3.62
B. Co		n of Average rate of Reduction under	Monopoly									
		S. No.	Drug(s)	Strength	Description	Route of		S.O. number & date				Reduction
						Administrat						with
						ion/						reference to
						Dosage						the highest
						Form &						PTR under
						packsize/pa						NLEM 2015 (%)
						cking, if any						
-		1	Lauradana (A) i Carbidana (B)	CR Tablet 100 mg (A)		Tablet		1252(5)	dated 29.3.2016			24.03%
		1	Levodopa (A) + Carbidopa (B)	+ 25 mg (B)		Tablet		1253(E) (	uateu 29.3.2016	•		24.03%
-		,	Levodopa (A) + Carbidopa (B)	+ 25 mg (B) 100mg+25mg Tablet		Tablet		1010 (5)	dated 18.5.2016			1.06%
-		2	Levodopa (A) + Carbidopa (B)  Levodopa (A) + Carbidopa (B)	100mg+25mg Tablet 100mg +10 mg Tablet		Tablet			dated 18.5.2016			0.78%
		3						` '				
		4	Levodopa (A) + Carbidopa (B)	250/25 MG tablet		Tablet			lated 15.09.201	6		0.32%
								Average Reduction				6.55%

		Computa	tion of Ceiling Price based on Aug 2015	Data under Para 6 of	DPCO 2013							
						Number of C	ompani	es cons	isting of Market	Share of 1% 8	& Above	1
	8.3.2	Cyclosporine	Injection 50 mg/ml	Per ML		Sum of MAT	value co	onsider	ed for price calc	ulation (in Lak	hs)	7.16
			-			PTR under Co	onsidera	ation				255.81
						% Reduction	with co	mpared	to Highest Pric	e (average)		16.86%
						Reduction as	per Mo	nopoly	condition			43.13
						PTR after Red	duction					212.68
						Add : 16% Re	etailer N	1argin				34.03
									taxes) (wef. 10.3	3.2016)		246.71
									6 @ -2.7105%			6.69
						Final Ceiling I	Price (w	ithout l	ocal taxes) (wef	. 01.4.2016 or	date of notification, whichever is later)	240.02
		Inder consideration							TOTAL MAT	715,976		
		Composition as per	पैक विवरण	छाप	कंपनी	Strength	Pack	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per
		NLEM	Pack Description	BRAND	Company		Size					Unit
	per											Considered
	NLEM											(Rs.)
1	8.3.2	CYCLOSPORIN   L4A4	SANDIMMUN 50 MG INJECTION 1 ML	SANDIMMUN	NOVARTIS INDIA LTD	50 MG	1	ML	255.81	715,976	100.00%	255.81
B. Co			luction under Monopoly			<del> </del>			l			
		S. No.	Drug(s)	Strength	Description	Route of		S.O. n	umber & date			Reduction
						Administrat						with
						ion/						reference to
						Dosage						the highest
						Form &						PTR under
						packsize/pa						NLEM 2015
						cking, if any						(%)
		1	Cyclosporine	Capsule 100 mg		Capsule		1 2	2195(E) dated 23	3.6.2016		19.24
		2	Cyclosporine	Capsule 50 mg		Capsule		2	2195(E) dated 23	3.6.2016		9.60
		3	Cyclosporine	Oral liquid 100		Oral liquid		2	2731(E) dated 1	7.8.2016		30.71
				mg/ml								
		4	Cyclosporine	25 MG capsule		Capsule		2	693(E) dated 15	.09.2016		7.90
								Avera	ge Reduction			16.86

		डीपीसीओ 2013 के पैरा 4 के	तहत, अगस्त 2015 के आंकड़ों के आधारि	त, मल्य की संग	गणना									
		Computation of Ceiling P	rice based on Aug-2015 Data under Par	a 4 of DPCO 2	013									
						Number of Co	mpanies co	onsisting of	Market Share o	f 1% & Above				8
	8.4.15	Zoledronic acid	Powder for Injection 4 mg	Each Pack		Sum of MAT v	alue consid	dered for pri	ce calculation (	(in Lakhs)				1,309.64
						Sum of PTR p	er unit cons	idered for p	rice calculation	ı				26500.20
						Number of Pa	icks conside	ered						8
						Average PTR								3312.53
						Add : 16% Re	tailer Margi	in						530.00
									ef. 10.3.2016)					3842.53
						% Reduction	with compa	red to Highe	est Price					77.14%
						WPI Reductio								104.15
						Final Ceiling F	rice (witho	ut local taxe	s) (wef. 01.4.20	016 or date of notific	ation, whichev	er is later)		3738.38
													1	
											Minimum Price			333.33
											Maximum Pric	<u> </u>		14488.57
											Average of all		Rs.)	3312.53
											Ceiling Price (F	Rs.)		3842.53
			* 0						TOTAL MAT	132,701,926			1	1
S.		Composition as per	पैक विवरण	छाप	कंपनी	Strength	<b>Pack Size</b>	Unit	PTR (Rs.)	MAT (Rs.)	SKU wise	Qualify	Price per	Price per Unit
No.	No. as										_			
1	1	NLEM	Pack Description	BRAND	Company						MAT %	(Y/N)	Unit (Rs.)	(Rs.)
	per NLEM	NLEM	Pack Description	BRAND	Company						MAT %	(Y/N) Y=Yes		
			·						2 000 00	15.000		(Y/N) Y=Yes N=No	Unit (Rs.)	(Rs.)
1	8.4.15	ZOLEDRONATE   M5A8	DRONICAD 4 MG INJECTION 1	DRONICAD	CADILA PHARMACEUTICALS LTD	4 MG	1	Each Pack	2,000.00	16,000	0.01%	(Y/N) Y=Yes N=No	Unit (Rs.)	(Rs.)
1 2	8.4.15	ZOLEDRONATE   M5A8 ZOLEDRONATE   M5A8	DRONICAD 4 MG INJECTION 1 ZOLON 4 MG INJECTION 1 ML	DRONICAD ZOLON	CADILA PHARMACEUTICALS LTD CELON LABS	4 MG	1	Each Pack	735.00	285,180	0.01% 0.21%	(Y/N) Y=Yes N=No N	2,000.00 735.00	(Rs.) Considered
1 2 3	8.4.15	ZOLEDRONATE   M5A8 ZOLEDRONATE   M5A8 ZOLEDRONATE   M5A8	DRONICAD 4 MG INJECTION 1 ZOLON 4 MG INJECTION 1 ML ZOLDRIA 4 MG INJECTION 5 ML	DRONICAD ZOLON ZOLDRIA	CADILA PHARMACEUTICALS LTD CELON LABS CIPLA LTD.	4 MG 4 MG	1	Each Pack Each Pack	735.00 1,100.00	285,180 7,186,600	0.01% 0.21% 5.42%	(Y/N) Y=Yes N=No N N	2,000.00 735.00 1,100.00	(Rs.) Considered
1 2 3 4	8.4.15	ZOLEDRONATE   M5A8 ZOLEDRONATE   M5A8 ZOLEDRONATE   M5A8 ZOLEDRONATE   M5A8	DRONICAD 4 MG INJECTION 1 ZOLON 4 MG INJECTION 1 ML ZOLDRIA 4 MG INJECTION 5 ML ZYFOSS 4 MG INJECTION 1	DRONICAD ZOLON ZOLDRIA ZYFOSS	CADILA PHARMACEUTICALS LTD CELON LABS CIPLA LTD. DABUR INDIA LTD.	4 MG 4 MG 4 MG	1	Each Pack Each Pack Each Pack	735.00 1,100.00 2,256.20	285,180 7,186,600 18,827,989	0.01% 0.21% 5.42% 14.19%	(Y/N) Y=Yes N=No N N Y	2,000.00 735.00 1,100.00 2,256.20	(Rs.) Considered 1,100.00 2,256.20
1 2 3 4 5	8.4.15	ZOLEDRONATE   M5A8 ZOLEDRONATE   M5A8 ZOLEDRONATE   M5A8 ZOLEDRONATE   M5A8 ZOLEDRONATE   M5A8 ZOLEDRONATE   M5A8	DRONICAD 4 MG INJECTION 1 ZOLON 4 MG INJECTION 1 ML ZOLDRIA 4 MG INJECTION 5 ML ZYFOSS 4 MG INJECTION 1 BLAZTERE 4 MG INJECTION 1	DRONICAD ZOLON ZOLDRIA ZYFOSS BLAZTERE	CADILA PHARMACEUTICALS LTD CELON LABS CIPLA LTD. DABUR INDIA LTD. DR. REDDYS LABORATORIES LTD	4 MG 4 MG 4 MG 4 MG	1	Each Pack Each Pack Each Pack Each Pack	735.00 1,100.00 2,256.20 2,447.24	285,180 7,186,600 18,827,989 42,479,192	0.01% 0.21% 5.42% 14.19% 32.01%	(Y/N) Y=Yes N=No N N Y	2,000.00 735.00 1,100.00 2,256.20 2,447.24	(Rs.) Considered 1,100.00 2,256.20 2,447.24
1 2 3 4 5 6	8.4.15	ZOLEDRONATE   M5A8 ZOLEDRONATE   M5A8 ZOLEDRONATE   M5A8 ZOLEDRONATE   M5A8 ZOLEDRONATE   M5A8 ZOLEDRONATE   M5A8	DRONICAD 4 MG INJECTION 1 ZOLON 4 MG INJECTION 1 ML ZOLDRIA 4 MG INJECTION 5 ML ZYFOSS 4 MG INJECTION 1 BLAZTERE 4 MG INJECTION 1 ZOLASTA 4 MG INJECTION 10 ML	DRONICAD ZOLON ZOLDRIA ZYFOSS BLAZTERE ZOLASTA	CADILA PHARMACEUTICALS LTD CELON LABS CIPLA LTD. DABUR INDIA LTD. DR. REDDYS LABORATORIES LTD INTAS PHARMACEUTICALS LTD	4 MG 4 MG 4 MG 4 MG 4 MG	1 1 1 1 1	Each Pack Each Pack Each Pack Each Pack Each Pack	735.00 1,100.00 2,256.20 2,447.24 333.33	285,180 7,186,600 18,827,989 42,479,192 1,536,606	0.01% 0.21% 5.42% 14.19% 32.01% 1.16%	(Y/N) Y=Yes N=No N N Y Y Y Y Y Y Y	2,000.00 735.00 1,100.00 2,256.20 2,447.24 333.33	(Rs.) Considered 1,100.00 2,256.20
1 2 3 4 5 6 7	8.4.15	ZOLEDRONATE   M5A8	DRONICAD 4 MG INJECTION 1 ZOLON 4 MG INJECTION 1 ML ZOLDRIA 4 MG INJECTION 5 ML ZYFOSS 4 MG INJECTION 1 BLAZTERE 4 MG INJECTION 1 ZOLASTA 4 MG INJECTION 10 ML XOLNIC 4 MG INJECTION 1	DRONICAD ZOLON ZOLDRIA ZYFOSS BLAZTERE ZOLASTA XOLNIC	CADILA PHARMACEUTICALS LTD CELON LABS CIPLA LTD. DABUR INDIA LTD. DR. REDDYS LABORATORIES LTD INTAS PHARMACEUTICALS LTD KHANDELWAL LABORATORIES LTD	4 MG 4 MG 4 MG 4 MG 4 MG 4 MG	1	Each Pack Each Pack Each Pack Each Pack Each Pack Each Pack	735.00 1,100.00 2,256.20 2,447.24 333.33 1,200.00	285,180 7,186,600 18,827,989 42,479,192 1,536,606 55,200	0.01% 0.21% 5.42% 14.19% 32.01% 1.16% 0.04%	(Y/N) Y=Yes N=No N Y Y Y Y Y Y Y N	2,000.00 735.00 1,100.00 2,256.20 2,447.24 333.33 1,200.00	(Rs.) Considered 1,100.00 2,256.20 2,447.24 333.33
1 2 3 4 5 6 7	8.4.15	ZOLEDRONATE   M5A8	DRONICAD 4 MG INJECTION 1 ZOLON 4 MG INJECTION 1 ML ZOLDRIA 4 MG INJECTION 5 ML ZYFOSS 4 MG INJECTION 1 BLAZTERE 4 MG INJECTION 1 ZOLASTA 4 MG INJECTION 10 ML XOLNIC 4 MG INJECTION 1 ZOLONAT 4 MG INJECTION 1	DRONICAD ZOLON ZOLDRIA ZYFOSS BLAZTERE ZOLASTA XOLNIC ZOLDONAT	CADILA PHARMACEUTICALS LTD CELON LABS CIPLA LTD. DABUR INDIA LTD. DR. REDDYS LABORATORIES LTD INTAS PHARMACEUTICALS LTD KHANDELWAL LABORATORIES LTD NATCO PHARMA LTD	4 MG 4 MG 4 MG 4 MG 4 MG 4 MG 4 MG 4 MG	1 1 1 1 1	Each Pack	735.00 1,100.00 2,256.20 2,447.24 333.33 1,200.00 2,300.00	285,180 7,186,600 18,827,989 42,479,192 1,536,606 55,200 23,633,558	0.01% 0.21% 5.42% 14.19% 32.01% 1.16% 0.04% 17.81%	(Y/N) Y=Yes N=No N N Y Y Y Y Y Y Y Y Y N N Y	2,000.00 735.00 1,100.00 2,256.20 2,447.24 333.33 1,200.00 2,300.00	(Rs.) Considered 1,100.00 2,256.20 2,447.24
2 3 4 5 6 7 8 9	8.4.15	ZOLEDRONATE   M5A8	DRONICAD 4 MG INJECTION 1 ZOLON 4 MG INJECTION 1 ML ZOLDRIA 4 MG INJECTION 5 ML ZYFOSS 4 MG INJECTION 1 BLAZTERE 4 MG INJECTION 1 ZOLASTA 4 MG INJECTION 10 ML XOLNIC 4 MG INJECTION 1 ZOLDONAT 4 MG INJECTION 1 OSTEOMET 4 MG INJECTION 1	DRONICAD ZOLON ZOLDRIA ZYFOSS BLAZTERE ZOLASTA XOLNIC ZOLDONAT OSTEOMET	CADILA PHARMACEUTICALS LTD CELON LABS CIPLA LTD. DABUR INDIA LTD. DR. REDDYS LABORATORIES LTD INTAS PHARMACEUTICALS LTD KHANDELWAL LABORATORIES LTD NATCO PHARMA LTD NEON LABORATORIES LTD	4 MG 4 MG 4 MG 4 MG 4 MG 4 MG 4 MG 4 MG	1 1 1 1 1 1 1 1	Each Pack	735.00 1,100.00 2,256.20 2,447.24 333.33 1,200.00 2,300.00 2,900.00	285,180 7,186,600 18,827,989 42,479,192 1,536,606 55,200 23,633,558 66,700	0.01% 0.21% 5.42% 14.19% 32.01% 1.16% 0.04% 17.81% 0.05%	(Y/N) Y=Yes N=No  N  N  Y  Y  Y  Y  Y  Y  N  N  N  N  N	2,000.00 735.00 1,100.00 2,256.20 2,447.24 333.33 1,200.00 2,300.00	(Rs.) Considered 1,100.00 2,256.20 2,447.24 333.33 2,300.00
2 3 4 5 6 7 8 9	8.4.15	ZOLEDRONATE   M5A8	DRONICAD 4 MG INJECTION 1 ZOLON 4 MG INJECTION 1 ML ZOLDRIA 4 MG INJECTION 5 ML ZYFOSS 4 MG INJECTION 1 BLAZTERE 4 MG INJECTION 1 ZOLASTA 4 MG INJECTION 10 ML XOLNIC 4 MG INJECTION 1 ZOLDONAT 4 MG INJECTION 1 ZOLDONAT 4 MG INJECTION 1 OSTEOMET 4 MG INJECTION 1 ZOMETA 4 MG INJECTION 1	DRONICAD ZOLON ZOLDRIA ZYFOSS BLAZTERE ZOLASTA XOLNIC ZOLDONAT OSTEOMET ZOMETA	CADILA PHARMACEUTICALS LTD CELON LABS CIPLA LTD. DABUR INDIA LTD. DR. REDDYS LABORATORIES LTD INTAS PHARMACEUTICALS LTD KHANDELWAL LABORATORIES LTD NATCO PHARMA LTD NEON LABORATORIES LTD NOVARTIS INDIA LTD	4 MG 4 MG 4 MG 4 MG 4 MG 4 MG 4 MG 4 MG	1 1 1 1 1	Each Pack	735.00 1,100.00 2,256.20 2,447.24 333.33 1,200.00 2,300.00 2,900.00 14,488.57	285,180 7,186,600 18,827,989 42,479,192 1,536,606 55,200 23,633,558 66,700 9,084,333	0.01% 0.21% 5.42% 14.19% 32.01% 1.16% 0.04% 17.81% 0.05% 6.85%	(Y/N) Y=Yes N=No  N  N  Y  Y  Y  Y  Y  Y  Y  N  N  Y  Y	2,000.00 735.00 1,100.00 2,256.20 2,447.24 333.33 1,200.00 2,300.00 14,488.57	1,100.00 2,256.20 2,447.24 333.33 2,300.00
2 3 4 5 6 7 8 9 10	8.4.15	ZOLEDRONATE   M5A8	DRONICAD 4 MG INJECTION 1 ZOLON 4 MG INJECTION 1 ML ZOLDRIA 4 MG INJECTION 5 ML ZYFOSS 4 MG INJECTION 1 BLAZTERE 4 MG INJECTION 1 ZOLASTA 4 MG INJECTION 10 ML XOLNIC 4 MG INJECTION 1 ZOLDONAT 4 MG INJECTION 1 OSTEOMET 4 MG INJECTION 1 ZOMETA 4 MG INJECTION 5 ML ZOLETRUST 4 MG INJECTION 5 ML	DRONICAD ZOLON ZOLDRIA ZYFOSS BLAZTERE ZOLASTA XOLNIC ZOLDONAT OSTEOMET ZOMETA ZOLETRUST	CADILA PHARMACEUTICALS LTD CELON LABS CIPLA LTD. DABUR INDIA LTD. DR. REDDYS LABORATORIES LTD INTAS PHARMACEUTICALS LTD KHANDELWAL LABORATORIES LTD NATCO PHARMA LTD NEON LABORATORIES LTD NOVARTIS INDIA LTD PANACEA BIOTEC LTD	4 MG 4 MG 4 MG 4 MG 4 MG 4 MG 4 MG 4 MG	1 1 1 1 1 1 1 1	Each Pack	735.00 1,100.00 2,256.20 2,447.24 333.33 1,200.00 2,300.00 2,900.00 14,488.57 1,215.24	285,180 7,186,600 18,827,989 42,479,192 1,536,606 55,200 23,633,558 66,700 9,084,333 9,727,996	0.01% 0.21% 5.42% 14.19% 32.01% 1.16% 0.04% 17.81% 0.05% 6.85% 7.33%	(Y/N) Y=Yes N=No N Y Y Y Y Y Y Y Y Y N N Y Y Y Y Y Y Y	Unit (Rs.)  2,000.00  735.00  1,100.00  2,256.20  2,447.24  333.33  1,200.00  2,900.00  14,488.57  1,215.24	(Rs.) Considered 1,100.00 2,256.20 2,447.24 333.33 2,300.00
2 3 4 5 6 7 8 9 10 11	8.4.15	ZOLEDRONATE   M5A8	DRONICAD 4 MG INJECTION 1 ZOLON 4 MG INJECTION 1 ML ZOLDRIA 4 MG INJECTION 5 ML ZYFOSS 4 MG INJECTION 1 BLAZTERE 4 MG INJECTION 1 ZOLASTA 4 MG INJECTION 10 ML XOLNIC 4 MG INJECTION 1 ZOLDONAT 4 MG INJECTION 1 ZOLDONAT 4 MG INJECTION 1 ZOMETA 4 MG INJECTION 1 ZOMETA 4 MG INJECTION 5 ML ZOLETRUST 4 MG INJECTION 1 ZORRENT 4 MG INJECTION 1	DRONICAD ZOLON ZOLONIA ZYFOSS BLAZTERE ZOLASTA XOLNIC ZOLDONAT OSTEOMET ZOMETA ZOLETRUST ZORRENT	CADILA PHARMACEUTICALS LTD CELON LABS CIPLA LTD. DABUR INDIA LTD. DR. REDDYS LABORATORIES LTD INTAS PHARMACEUTICALS LTD KHANDELWAL LABORATORIES LTD NATCO PHARMA LTD NEON LABORATORIES LTD NOVARTIS INDIA LTD PANACEA BIOTEC LTD TORRENT PHARMACEUTICALS LTD.	4 MG	1 1 1 1 1 1 1 1	Each Pack	735.00 1,100.00 2,256.20 2,447.24 333.33 1,200.00 2,300.00 2,900.00 14,488.57 1,215.24 750.00	285,180 7,186,600 18,827,989 42,479,192 1,536,606 55,200 23,633,558 66,700 9,084,333 9,727,996 1,130,250	0.01% 0.21% 5.42% 14.19% 32.01% 1.16% 0.04% 17.31% 0.05% 6.85% 7.33% 0.85%	(Y/N) Y=Yes N=No N N Y Y Y Y Y Y Y N N Y N N Y N N N N	Unit (Rs.)  2,000.00 735.00 1,100.00 2,256.20 2,447.24 333.33 1,200.00 2,300.00 14,488.57 1,215.24 750.00	1,100.00 2,256.20 2,447.24 333.33 2,300.00
2 3 4 5 6 7 8 9 10	8.4.15	ZOLEDRONATE   M5A8	DRONICAD 4 MG INJECTION 1 ZOLON 4 MG INJECTION 1 ML ZOLDRIA 4 MG INJECTION 5 ML ZYFOSS 4 MG INJECTION 1 BLAZTERE 4 MG INJECTION 1 ZOLASTA 4 MG INJECTION 10 ML XOLNIC 4 MG INJECTION 1 ZOLDONAT 4 MG INJECTION 1 OSTEOMET 4 MG INJECTION 1 ZOMETA 4 MG INJECTION 5 ML ZOLETRUST 4 MG INJECTION 5 ML	DRONICAD ZOLON ZOLDRIA ZYFOSS BLAZTERE ZOLASTA XOLNIC ZOLDONAT OSTEOMET ZOMETA ZOLETRUST ZORRENT ZOLDARO	CADILA PHARMACEUTICALS LTD CELON LABS CIPLA LTD. DABUR INDIA LTD. DR. REDDYS LABORATORIES LTD INTAS PHARMACEUTICALS LTD KHANDELWAL LABORATORIES LTD NATCO PHARMA LTD NEON LABORATORIES LTD NOVARTIS INDIA LTD PANACEA BIOTEC LTD	4 MG 4 MG 4 MG 4 MG 4 MG 4 MG 4 MG 4 MG	1 1 1 1 1 1 1 1	Each Pack	735.00 1,100.00 2,256.20 2,447.24 333.33 1,200.00 2,300.00 2,900.00 14,488.57 1,215.24	285,180 7,186,600 18,827,989 42,479,192 1,536,606 55,200 23,633,558 66,700 9,084,333 9,727,996	0.01% 0.21% 5.42% 14.19% 32.01% 1.16% 0.04% 17.81% 0.05% 6.85% 7.33%	(Y/N) Y=Yes N=No N Y Y Y Y Y Y Y Y Y N N Y Y Y Y Y Y Y	Unit (Rs.)  2,000.00  735.00  1,100.00  2,256.20  2,447.24  333.33  1,200.00  2,900.00  14,488.57  1,215.24	1,100.00 2,256.20 2,447.24 333.33 2,300.00

		डीपीसीओ 2013 के पैरा 4	के तहत, अगस्त 2015 के आंकड़ों के आ	धारित, मूल्य की	संगणना									
		<b>Computation of Ceiling</b>	Price based on Aug-2015 Data under	r Para 4 of DPCO	2013									
						Number of Co	mpanies	consisting o	f Market Share	of 1% & Above				2
	6.4.2.1	Ganciclovir	Capsule 250 mg	Per Capsule		Sum of MAT v	alue cons	idered for p	rice calculation	(in Lakhs)				219.37
						Sum of PTR pe	er unit cor	nsidered for	price calculation	on				189.57
						Number of Pa	cks consid	lered						2
						Average PTR								94.79
						Add: 16% Ret	ailer Mar	gin						15.17
						Ceiling Price (	without lo	cal taxes) (v	wef. 10.3.2016)					109.96
						% Reduction v	with comp	ared to Hig	hest Price					2.28%
						WPI Reduction	n wef 1.4.	2016 @ -2.7	7105%					2.98
						Final Ceiling P	rice (with	out local tax	kes) (wef. 01.4.2	2016 or date of no	otification, which	never is later	)	106.98
											Minimum Price	(Rs.)		92.57
											Maximum Price	e (Rs.)		97.00
											Average of all o	onsidered (R	s.)	94.79
											Ceiling Price (R	s.)		109.96
									TOTAL MAT	21,936,606	100%			
s.	Unique	Composition as per	पैक विवरण	छाप	कंपनी	Strength	Pack	Unit	PTR (Rs.)	MAT (Rs.)	SKU wise	Qualify	Price per	Price per Unit
No.	No. as	NLEM	Pack Description	BRAND	Company		Size				MAT %	(Y/N)	Unit (Rs.)	(Rs.) Considered
	per											Y=Yes		
	NLEM											N=No		
	1 6.4.2.1	GANCYCLOVIR   J5A9	CYTOGAN 250 MG CAPSULE 10	CYTOGAN	ABBOTT HEALTHCARE PVT. LTD	250 MG	10	CAPSULE	970.00	1,304,650	5.95%	Υ	97.00	97.00
	2	GANCYCLOVIR   J5A9	NATCLOVIR 250 MG CAPSULE 10	NATCLOVIR	NATCO PHARMA LTD	250 MG	10	CAPSULE	925.71	20,631,956	94.05%	Υ	92.57	92.57

		Comput	ation of Ceiling Price based on Aug 20	15 Data under	Para 6 of DPCO 2013							
						Number of C	ompanies co	nsisting of Mar	rket Share of 1%	& Above		1
	2.2.3	Tramadol	100 mg capsule	Per Capsule		Sum of MAT	value consid	lered for price of	calculation (in La	khs)		0.23
						PTR under Co	nsideration					10.66
						% Reduction	with compar	red to Highest I	Price (average)			25.96%
						Reduction as	per Monopo	oly condition				2.77
						PTR after Red	luction					7.89
						Add : 16% Re						1.26
								al taxes) (wef. 1				9.15
								016 @ -2.71059				0.25
						Final Ceiling	Price (withou	ut local taxes) (	wef. 01.4.2016 o	r date of notification,	whichever is later)	8.90
		nder consideration							TOTAL MAT	22,608		
		р	पैक विवरण	छाप	कंपनी	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit
No.	No. as	NLEM	Pack Description	BRAND	Company							Considered
	per											(Rs.)
	NLEM											
1	2.2.3	TRAMADOL   N2B5	TAKOL CR 100 MG CAPSULE CR 10	TAKOL CR	RAPTAKOS, BRETT & CO. LTD.	100 MG	10	CAPSULE CR	106.64	22,608	100.00%	10.66
D 6-		-f 4	duration and an Board and the									
B. Co	. •		duction under Monopoly						1			
		S. No.	Drug(s)	Strength	Description	Route of		S.O. number	& date			Reduction
						Administrat						with reference
						ion/						to the highest
						Dosage						PTR under
						Form &						NLEM 2015 (%)
						packsize/pa						
						cking, if any						
		1	Tramadol	50 mg	50 mg capsule	Capsule		S.O. N	o. 2195 (E) dated	23.06.2016		32.73
				capsule	J P	.,,			,			
		2	Tramadol	50mg/ml	1 ML & 2 ML Pack	Injection		Proposed in o	urrent 43th med	eting		22.57
		3	Tramadol	50mg/ml	20 ML Pack	Injection		Proposed in o	urrent 43th med	eting		22.57
								Average Redu	uction			25.96

		1							1	1		
		Computa	tion of Ceiling Price based on Aug 2015	Data under Pa	era 6 of DPCO 2013							
		computa	lion of ceiling thee based on Aug 2015		100000000000000000000000000000000000000	Number of C	ompanies co	nsisting o	of Market Share	of 1% & Above		1
	2.2.3	Tramadol	Injection 50 mg/ml	Per ML			•		price calculation			0.47
			,	(20 ML Pack)		PTR under Co						1.43
-				<u>'</u>					I ghest Price (avera	age)		27.65%
						Reduction as	•			360/		0.40
				1		PTR after Red		l comun	1			1.03
						Add : 16% Re		n				0.16
									wef. 10.3.2016)			1.19
						WPI Reduction	•		•			0.03
			S.O. 619(E) dated 26.02.2015			Final Ceiling I	Price (withou	ıt local ta	xes) (wef. 01.4.2	016 or date of notific	cation, whichever is later)	1.16
			Ceiling Price as per NLEM 2011	12.95	Per ML	Ī	,				•	
			Derived Ceiling PTR	11.16								
A. Li	st of Item I	Under consideration							TOTAL MAT	46,679		
S.	Unique	Composition as per	पैक विवरण	छाप	कंपनी	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit
No.	No. as	NLEM	Pack Description	BRAND	Company							Considered
	per											(Rs.)
	NLEM											
1	2.2.3	TRAMADOL   N2B5	URGENDOL 50 MG INJECTION 20 ML	URGENDOL	WIN-MEDICARE PVT. LTD.	50 MG	20	ML	28.69	46,679	100.00%	1.43
B. C	omputatio		eduction under Monopoly	1								
		S. No.	Drug(s)	Strength	Description	Route of		S.O. nui	mber & date			Reduction
						Administrat						with
						ion/						reference to
						Dosage						the highest
						Form &						PTR under
						packsize/pa						NLEM 2015 (%)
						cking, if any						
		1	Tramadol	50 mg	50 mg capsule	Capsule		S.O	. No. 2195 (E) da	ted 23.06.2016		32.73
				capsule								
		2	Tramadol	50mg/ml	1 ML & 2 ML Pack	Injection			ed in current 43t	h meeting		22.57
								Average	Reduction			27.65

		10000													
			4 के तहत, अगस्त 2015 के आंकड़ों के आधारि	, .											
		Computation of Ceilin	g Price based on Aug-2015 Data under Pa	ra 4 of DPCO 2013		<del> </del>									
										hare of 1% & Above	e		1		12
	2.2.3	Tramadol	Injection 50 mg/ml	Per ML	1				ed for price calcul				1		644.75
				(1 ML & 2 ML Pa	ICK)		_		red for price calc	ulation			1		129.15
				-		Number of		isiaerea	1				-		15 <b>8.61</b>
						Average PT						-	1		1.38
						Add : 16% I			axes) (wef. 10.3.2	2016)	-	+		+	9.99
									to Highest Price						22.57%
									6 @ -2.7105%				1		0.27
										01.4.2016 or date o	f notification w	hichever is later	1	+	9.72
						i indi ceiini	, i rice (w	I	ocui tuxes/ (wei.	01.4.2010 OF GUIC O	i notineation, w	THETICVET IS IDECT	1	+	5.72
											Minimum Pric	e (Rs.)			1.73
					S.O. 619(E) dated 26.02.2015						Maximum Pric	- ( - /			11.12
					Ceiling Price as per NLEM 2011	12.95	Per ML					considered (Rs.)			8.61
					Derived Ceiling PTR	11.16			1		Ceiling Price (F			1	9.99
											, , , , , , , , , ,	Ī			0.00
					İ				TOTAL MAT	65,517,173	100%	3	•	•	•
S.	Unique	Composition as per	पैक विवरण	छाप	कंपनी	Strength	Pack	Unit	PTR (Rs.)	MAT (Rs.)	SKU wise	Company	Qualify	Price per	Price per Unit
No.	No. as per	NLEM	Pack Description	BRAND	Company		Size		, ,		MAT %	Levelwise	(Y/N)	Unit (Rs.)	(Rs.)
	NLEM		•									MAT	(Y=Yes		Considered
												(ignoring O%	N=No)		
												MAT)	-		
1	2.2.3	TRAMADOL   N2B5	CONTRAMAL 50 MG INJECTION 1 ML	CONTRAMAL	ABBOTT HEALTHCARE PVT. LTD	50 MG	1	ML	10.08	4,360,252	6.66%	6.66%	Υ	10.08	10.08
2		TRAMADOL   N2B5	TERMEG 50 MG INJECTION 1 ML	TERMEG	ALEMBIC LTD	50 MG	1	ML	3.33	49,727	0.08%	0.08%	N	3.33	
3		TRAMADOL   N2B5	TRAMEF 50 MG INJECTION 2 ML	TRAMEF	ALKEM LABORATORIES LTD.	50 MG	2	ML	4.00	60,364	0.09%	0.09%	N	2.00	
4		TRAMADOL   N2B5	ULTRAMOL 50 MG INJECTION 1 ML	ULTRAMOL	ARISTO PHARMACEUTICALS PVT.LTD	50 MG	1	ML	55.83	43,882	0.07%	0.07%	N	55.83	
5		TRAMADOL   N2B5	BESTODOL 50 MG INJECTION 1 ML	BESTODOL	BESTOCHEM FORMULATIONS (I) LTD	50 MG	1	ML	19.89	288,494	0.44%	0.44%	N	19.89	
6		TRAMADOL   N2B5	BIOTRAM 50 MG INJECTION 2 ML	BIOTRAM	BIOCHEM PHARMACEUTICAL INDS	50 MG	2	ML	4.00	868,283	1.33%	1.33%	Υ	2.00	2.00
7		TRAMADOL   N2B5	EUPHODOL 50 MG INJECTION 2 ML	EUPHODOL	EUPHORIC PHARMACEUTICALS (P) LTD	50 MG	2	ML	15.98	109,048	0.17%	0.17%	N	7.99	
8		TRAMADOL   N2B5	TRAMATAS 50 MG INJECTION 2 ML	TRAMATAS	INTAS PHARMACEUTICALS LTD	50 MG	2	ML	3.45	2,155,205	3.29%	3.29%	Υ	1.73	1.73
9		TRAMADOL   N2B5	KAMADOL 50 MG INJECTION 1 ML	KAMADOL	KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LTD(KAPL)	50 MG	1	ML	10.28	2,043,817	3.12%	3.12%	Υ	10.28	10.28
10		TRAMADOL   N2B5	KEDOL 50 MG INJECTION 2 ML	KEDOL	KEEN PHARAMCEUTICALS	50 MG	2	ML	19.64	161,068	0.25%	0.25%	N	9.82	
11		TRAMADOL   N2B5	ZAMADOL 50 MG INJECTION 1 ML	ZAMADOL	MACLEODS PHARMACEUTICALS PVT.LTD	50 MG	1	ML	8.27	29,259	0.04%	0.04%	N	8.27	+
12 13		TRAMADOL   N2B5 TRAMADOL   N2B5	TDX 50 MG INJECTION 2 ML	TDX ULTRAM	MARC PHARMA	50 MG 50 MG	2	ML ML	20.00	6,720 1.342.503	0.01% <b>2.05%</b>	0.01% <b>2.05%</b>	N Y	10.00 9.49	9.49
14		TRAMADOL   N2B5	ULTRAM 50 MG INJECTION 1 ML SUPRIDOL 50 MG INJECTION 1 ML	SUPRIDOL	MICRO LABS LTD NEON LABORATORIES LTD	50 MG	1	ML	9.49 7.60	1,342,503	2.05%	2.05%	Y	7.60	7.60
15		TRAMADOL   N2B5	ULTRAMED 50 MG INJECTION 1 ML	ULTRAMED	PHARMED LTD	50 MG	2	ML	17.52	7,127,154	10.88%	10.88%	Y	8.76	8.76
16		TRAMADOL   N2B5	TRAMBAX 50 MG INJECTION 1 ML	TRAMBAX	SUN PHARMA (RANBAXY LABORATORIES LTD)	50 MG	1	ML	78.28	131,745	0.20%	0.28%	N	78.28	0.70
17		TRAMADOL   N2B5	TRANZEX 50 MG INJECTION 1 ML	TRANZEX	SUN PHARMA (RANBAXY LABORATORIES LTD)	50 MG	2	ML	5.00	50.925	0.20%	0.28%	N	2.50	<del>                                     </del>
18		TRAMADOL   N2B5	RAMCET 50 MG INJECTION 1 ML	RAMCET	SUNDYOTA NUMANDIS PHARMA PVT LTD	50 MG	1	ML	9.38	1,340,787	2.05%	2.05%	Y	9.38	9.38
19		TRAMADOL   N2B5	CENTRADOL 50 MG INJECTION 1 ML	CENTRADOL	TABLETS INDIA LTD	50 MG	1	ML	8.30	952,754	1.45%	1.45%	Y	8.30	8.30
20		TRAMADOL   N2B5	DOMADOL 50 MG INJECTION 1 ML	DOMADOL	UNICHEM LABORATORIES LTD	50 MG	1	ML	11.12	4,100,144	6.26%	6.26%	Υ	11.12	11.12
21		TRAMADOL   N2B5	MERIDOL 50 MG INJECTION 1 ML	MERIDOL	UNIMARCK HEALTHCARE LTD	50 MG	1	ML	11.54	47,360	0.07%	0.07%	N	11.54	<del> </del>
22		TRAMADOL   N2B5	URGENDOL 50 MG INJECTION 1 ML	URGENDOL	WIN-MEDICARE PVT. LTD.	50 MG	1	ML	9.14	3,369,589	5.14%	16.52%	Υ	9.14	9.14
23		TRAMADOL   N2B5	URGENDOL 50 MG INJECTION 2 ML	URGENDOL	WIN-MEDICARE PVT. LTD.	50 MG	2	ML	19.81	7,458,331	11.38%	16.52%	Υ	9.91	9.91
24		TRAMADOL   N2B5	TRANZAT 50 MG INJECTION 2 ML	TRANZAT	WOCKHARDT LTD	50 MG	2	ML	3.50	36,145	0.06%	0.06%	N	1.75	
25		TRAMADOL   N2B5	NEXDOL 50 MG INJECTION 1 ML	NEXDOL	ZUVENTUS HEALTHCARE LTD	50 MG	1	ML	12.54	27,387	0.04%	0.04%	N	12.54	
26		TRAMADOL   N2B5	TRAMAZAC 50 MG INJECTION 1 ML	TRAMAZAC	ZYDUS CADILA	50 MG	1	ML	10.45	24,225,081	36.98%	42.27%	Υ	10.45	10.45
27		TRAMADOL   N2B5	TRAMAZAC HP 50 MG INJECTION 2 ML	TRAMAZAC HP	ZYDUS CADILA	50 MG	2	ML	20.91	1,333,428	2.04%	42.27%	Y	10.46	10.46

		डीपीसीओ 2013 के पैरा 4 के तहत	ा, अगस्त 2015 के आंकड़ों के आधारित, म	ल्य की संगणना											
		Computation of Ceiling Price b	ased on Aug-2015 Data under Para 4	of DPCO 2013											
						Number of Co	mpanies c	onsistin	g of Market Shar	e of 1% & Above					3
	8.4.10	Metoclopramide	Injection 5mg/ml	Per ML		Sum of MAT va	alue consi	dered fo	or price calculatio	n (in Lakhs)					611.78
				(10 ML Pack)		Sum of PTR pe	r unit con	sidered	for price calculat	ion					3.52
						Number of Pag	ks consid	ered							3
						Average PTR									1.17
						Add : 16% Reta	ailer Marg	in							0.19
						Ceiling Price (v	vithout lo	cal taxe	s) (wef. 10.3.2016	5)					1.36
						% Reduction with compared to Highest									4.10%
						WPI Reduction									0.04
						Final Ceiling Pr	ice (witho	ut local	l taxes) (wef. 01.4	.2016 or date of I	notification, wh	ichever is later)			1.32
											Minimum Price	e (Rs.)			1.11
					S.O. 619(E) dated 26.02.2015						Maximum Pric				1.22
					Ceiling Price as per NLEM 2011	2.31	Per ML					considered (Rs.)			1.17
					Deirved Ceiling PTR	1.99					Ceiling Price (F	ts.)			1.36
									TOTAL MAT	61,177,720	100%				
s.	Unique	Composition as per NLEM	पैक विवरण	छाप	कंपनी	Strength	Pack	Unit	PTR (Rs.)	MAT (Rs.)	SKU wise	Company	Qualify	Price per	Price per Unit
No	. No. as per		Pack Description	BRAND	Company		Size				MAT %	Levelwise	(Y/N)	Unit (Rs.)	(Rs.)
	NLEM											MAT	(Y=Yes		Considered
												(ignoring O%	N=No)		
												MAT)			
	1 8.4.10		REGLAN 5 MG INJECTION 10 ML	REGLAN	ADCOCK INGRAM HEALTHCARE PVT LTD	5 MG	10	ML	12.22	22,967,922	37.54%	37.54%	Υ	1.22	1.22
	2		PERINORM 5 MG INJECTION 10 ML	PERINORM	IPCA LABORATORIES PVT LTD.	5 MG	10	ML	11.14	35,539,340	58.09%	58.09%	Υ	1.11	1.11
	3	METOCLOPRAMIDE   A3F19	MAXERON 5 MG INJECTION 10 ML	MAXERON	WALLACE PHARMACEUTICALS LTD.	5 MG	10	ML	11.87	2,670,458	4.37%	4.37%	Y	1.19	1.19

		डीपीसीओ 2013 के पैरा 4 के तहत, अ	गस्त 2015 के आंकड़ों के आधारित, मूल्य	की संगणना											
		Computation of Ceiling Price based	d on Aug-2015 Data under Para 4 of D	PCO 2013											
						Number of Companies consisting of Market Share of 1% & Above									2
	8.4.10	Metoclopramide	Injection 5mg/ml (Single-use)	Per ML		Sum of MAT va	alue consi	dered fo	or price calculation	on (in Lakhs)					562.17
						Sum of PTR pe	r unit con	sidered	for price calculat	tion					3.86
						Number of Pac	ks consid	ered							2
						Average PTR									1.93
						Add : 16% Reta	ailer Marg	gin							0.31
						Ceiling Price (w	Ceiling Price (without local taxes) (wef. 10.3.2016)								2.24
						% Reduction with compared to Highest Price									0.52%
						WPI Reduction wef 1.4.2016 @ -2.7105%									0.06
						Final Ceiling Pr	ice (with	out loca	I taxes) (wef. 01.4	4.2016 or date of	notification, wh	nichever is later)			2.18
											Minimum Price	e (Rs.)			1.92
					S.O. 619(E) dated 26.02.2015						Maximum Pric	e (Rs.)			1.94
					Ceiling Price as per NLEM 2011	2.31	Per ML				Average of all	considered (Rs.)			1.93
					Deirved Ceiling PTR	1.99					Ceiling Price (F	Rs.)			2.24
									TOTAL MAT	56,216,961	100%				
S.	Unique	Composition as per NLEM	पैक विवरण	छाप	कंपनी	Strength	Pack	Unit	PTR (Rs.)	MAT (Rs.)	SKU wise	Company	Qualify	Price per	Price per Unit
No.	No. as		Pack Description	BRAND	Company		Size				MAT %	Levelwise	(Y/N)	Unit (Rs.)	(Rs.)
	per											MAT	(Y=Yes		Considered
	NLEM											(ignoring O%	N=No)		
												MAT)			
1		METOCLOPRAMIDE   A3F19	REGLAN 5 MG INJECTION 2 ML	REGLAN	ADCOCK INGRAM HEALTHCARE PVT LTD	5 MG	2	ML	3.83	15,091,916	26.85%	26.85%	Y	1.92	1.92
2	2	METOCLOPRAMIDE   A3F19	PERINORM 5 MG INJECTION 2 ML	PERINORM	IPCA LABORATORIES PVT LTD.	5 MG	2	ML	3.87	41,125,045	73.15%	73.15%	Y	1.94	1.94

	1							1	1			1
-		Compu	tation of Ceiling Price based on Aug 2	015 Data under Da	ara 6 of DBCO 2013							
		Compa	tation of ceiling rince based on Aug 2	Data under Fa		Number of C	omnanies co	nsisting o	f Market Share o	of 1% & Ahove		1
	21.3.2	Levonorgestrel	Tablet 0.75 mg					rice calculation			4102.98	
	LIIJIL	zevono.gest.e.	radict 0.75 mg	Per tablet		PTR under Co		1		(iii Lakiis)		32.00
						_		red to Hig	nest Price (avera	ge)		3.63%
						Reduction as			•	-8-7		1.16
						PTR after Red		1	l			30.84
						Add : 16% Re		1				4.93
									wef. 10.3.2016)			35.77
						WPI Reduction						0.97
										016 or date of no	tification, whichever is later)	34.80
			1									
A. Lis	t of Item U	nder consideration							TOTAL MAT	412,694,557	100.00%	
S.	Unique	Composition as per NLEM	पैक विवरण	छाप	कंपनी	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit
	No. as		Pack Description	BRAND	Company							Considered
	per NLEM											(Rs.)
1	21.3.2	LEVONORGESTREL   G3A13	UNWANTED 72 0.75 MG TABLET 2	UNWANTED 72	MANKIND PHARMACEUTICALS LTD.	0.75 MG	2	TABLET	64.00	410,297,792	99.42%	32.00
		LEVONORGESTREL   G3A13	NORLEVO 0.75 MG TABLET 2	NORLEVO	WIN-MEDICARE PVT. LTD.	0.75 MG	2	TABLET	39.28	2,396,765	0.58%	
B. Co	mputation	of Average rate of Reduction	under Monopoly									
		S. No.	Drug(s)	Strength	Description	Route of		S.O. nun	nber & date			Reduction
						Administrati						with reference
						on/ Dosage						to the highest
						Form &						PTR under
						packsize/pa						NLEM 2015 (%)
						cking, if any						
								<u> </u>			_	
		1	Ethinylestradiol	Tablet 0.01 mg	Tablet 0.01 mg	tablet		S.O. No.	2569 (E) dated 2	29.07.2016		3.63
			Ethinylestradiol	Tablet 0.05 mg	Tablet 0.05 mg	tablet		S.O. No.	4127 (E) dated 2	22.12.2016		3.63
								Average	Reduction		<del></del>	3.63

		Computati	on of Ceiling Price based on Aug 201	L5 Data under Pa	ara 6 of DPCO 2013							
						Number of C	ompanies co	nsisting o	f Market Share o	f 1% & Above		1
	21.1.3	Hydrocortisone	Tablet 10 mg	Per Tablet		Sum of MAT value considered for price calculation (in Lakhs)						
						PTR under Co	nsideration					5.36
						% Reduction	with compar	red to Hig	hest Price (avera	ge)		13.19%
						Reduction as	per Monopo	oly conditi	on			0.71
						PTR after Rec	luction					4.65
						Add : 16% Re	tailer Margir	n				0.74
						Ceiling Price	without loca	al taxes) (	wef. 10.3.2016)			5.39
						WPI Reduction						0.15
						Final Ceiling I	rice (withou	ut local ta	xes) (wef. 01.4.20	016 or date of notific	ation, whichever is later)	5.24
		der consideration							TOTAL MAT	17,229,613		
S. No.		Composition as per NLEM	पैक विवरण	छाप	कंपनी	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit
	No. as		Pack Description	BRAND	Company							Considered
	per NLEM											(Rs.)
1	21.1.3	HYDROCORTISONE   H2A7	HISONE(SMR) 10 MG TABLET 10	HISONE(SMR)	SAMARTH LIFE SCIENCES PVT LTD	10 MG	10	TABLET	53.60	17,229,613	100.00%	5.36
B. Con		of Average rate of Reduction un							L			
		S. No.	Drug(s)	Strength	Description	Route of		S.O. nur	nber & date			Reduction
						Administrati						with reference
						on/ Dosage						to the highest
						Form &						PTR under
						packsize/pa						NLEM 2015 (%)
						cking, if any						
			1 Hydrocortisone	Injection 100	Injection 100 mg/ml	injection		S.O	. No. 1686 (E) da	ted 09.05.2016		13.19
				mg/ml								
				1				Average	Reduction			13.19

		Computation	on of Ceiling Price based on Aug 20	15 Data under Pa	ara 6 of DPCO 2013							
						Number of C	ompanies co	nsisting o	f Market Share o	f 1% & Above		1
	21.1.3	Hydrocortisone		Sum of MAT	value consid	ered for p	rice calculation (	in Lakhs)		95.53		
						PTR under Co	nsideration					2.76
							with compar	ed to Hig	hest Price (avera	ge)		13.19%
						Reduction as	per Monopo	oly conditi	on			0.36
						PTR after Rec	luction					2.40
						Add: 16% Re	tailer Margir	i				0.38
						Ceiling Price	without loca	al taxes) (	wef. 10.3.2016)			2.78
							NPI Reduction wef 1.4.2016 @ -2.7105%					0.08
						Final Ceiling I	Price (withou	ıt local ta	kes) (wef. 01.4.20	016 or date of notific	cation, whichever is later)	2.70
A. Lis	t of Item U	Inder consideration							TOTAL MAT	9,553,095		
s.	Unique	Composition as per NLEM	पैक विवरण	छाप	कंपनी	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit
No.	No. as		Pack Description	BRAND	Company							Considered
	per NLEM											(Rs.)
1	21.1.3	HYDROCORTISONE   H2A7	HISONE(SMR) 5 MG TABLET 10	HISONE(SMR)	SAMARTH LIFE SCIENCES PVT LTD	5 MG	10	TABLET	27.62	9,553,095	100.00%	2.76
B. Co		of Average rate of Reduction u										
		S. No.	Drug(s)	Strength	Description	Route of		S.O. nur	nber & date			Reduction
						Administrati						with reference
						on/ Dosage						to the highest
						Form &						PTR under
						packsize/pa						NLEM 2015 (%)
						cking, if any						
		1 Hydrocortisone Injection 100 Injection 100 mg/ml		Injection 100 mg/ml	injection		S.O	. No. 1686 (E) da	ted 09.05.2016		13.19	
				mg/ml								
								Average	Reduction			13.19
		1	I.	1	L	1				l .	1	